- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02148471
Fatty Acids, Genes and Microbiota in Fatty Liver
Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation?
Przegląd badań
Status
Szczegółowy opis
NASH is associated with obesity, diabetes and hyperlipidemia. Fat accumulation in the liver is likely due to variable degrees of disordered fatty-acid metabolism and insulin resistance (IR). Liver steatosis, especially polyunsaturated fatty acids (PUFA) in the liver, increases lipid peroxidation and is associated with a reduction in the antioxidant defense system. This oxidative stress can lead to increased production of pro-inflammatory cytokines (TNF-α, transforming growth factor-beta) contributing to the development of steatohepatitis and fibrosis.TNF-α - may further contribute to IR. In addition, changes in fatty acid composition within the liver may influence lipid metabolism and inflammation. In particular, n-3 PUFA have an effect on the insulin sensitivity, transcription of antioxidant genes, inflammatory response and production of reactive oxygen species. Differences might be seen on the gene expression level (mRNA) and also in epigenetic regulation (miRNA).
Microbiota composition might influence energy metabolism, and inflammatory tone and IR through increased endotoxemia and therefore could also play a role in the development of NAFLD.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Ontario
-
Toronto, Ontario, Kanada, M5G 1Z5
- Toronto General Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion criteria:
- Male and female patients, age >18 y
- A liver biopsy with a diagnosis of SS or NASH OR No signs of steatosis, fibrosis or any other kind of liver disease on histology (minimal findings) OR For healthy control subjects, those with normal liver enzymes and normal liver imaging on ultrasound
- alcohol consumption (<20g of ethanol per day);
- absence of any other possible cause for liver dysfunction.
Exclusion criteria:
- any other liver disease apart from NAFLD
- anticipated need for liver transplantation in one year or complications of liver disease;
- any reasons contraindicating a liver biopsy (patients) or liver donation (healthy donors)
- chronic gastrointestinal diseases, previous gastrointestinal surgery modifying the anatomy, patients with diabetes requiring insulin.
- medications known to precipitate steatohepatitis (corticosteroids, high dose estrogens, methotrexate, amiodarone, spironolactone, sulfasalazine, perhexiline maleate, diethylamino- ethoxyhexestrol (DH), tamoxifen, diethylstilbestrol, naproxen or oxacillin) or regular intake of non-steroidal anti-inflammatory drugs (except for low dose aspirin), use of ursodeoxycholic acid or any experimental drug in the 6 months prior to entry.
- regular intake of prebiotics, probiotics, antibiotics, or laxatives; in the 3 months prior to study entry
- Pregnant or lactating
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: Kohorta
- Perspektywy czasowe: Przekrojowe
Kohorty i interwencje
Grupa / Kohorta |
---|
Healthy controls
Healthy living liver donors with healthy liver on imaging and/or liver histology
|
Simple steatosis
Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of simple steatosis
|
Nonalcoholic steatohepatitis
Patients with non-alcoholic fatty liver disease confirmed by liver biopsy with a diagnosis of steatohepatitis
|
Minimal findings
Patients undergoing liver biopsy because of suspected fatty liver but nonspecific findings on liver histology.
This group was initially used as a control group.
Later in the study, this group was replaced by healthy donors as true healthy controls.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Hepatic fatty acid composition in total lipids in liver biopsy
Ramy czasowe: Baseline
|
Gas chromatography
|
Baseline
|
Hepatic gene expression
Ramy czasowe: Baseline
|
mRNA by microarray
|
Baseline
|
Intestinal microbiota composition
Ramy czasowe: Baseline
|
Illumina 16S technology
|
Baseline
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Lipid peroxides in the liver
Ramy czasowe: Baseline
|
Test kit
|
Baseline
|
Hepatic liver antioxidant power
Ramy czasowe: Baseline
|
Test kit
|
Baseline
|
Hepatic microRNA expression in the liver
Ramy czasowe: Baseline
|
NanoString
|
Baseline
|
Intestinal microbiota - specific organisms and groups
Ramy czasowe: Baseline
|
Quantitative real-time polymerase chain reaction
|
Baseline
|
Intestinal microbiome on a genetic level
Ramy czasowe: Baseline
|
Illumina sequencing technology
|
Baseline
|
Short-chain fatty acids in stool
Ramy czasowe: Baseline
|
Gas chromatography
|
Baseline
|
Plasma endotoxin
Ramy czasowe: Baseline
|
Limulus assay
|
Baseline
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Hepatic phospholipid composition
Ramy czasowe: Baseline
|
Gas chromatography
|
Baseline
|
Red blood cell fatty acid and phospholipid composition
Ramy czasowe: Baseline
|
Gas chromatography
|
Baseline
|
Plasma fatty acid composition
Ramy czasowe: Baseline
|
Gas chromatography
|
Baseline
|
Plasma lipid peroxides
Ramy czasowe: Baseline
|
Test kit
|
Baseline
|
Plasma antioxidant vitamins
Ramy czasowe: Baseline
|
Vitamin C colorimetric, alpha- and gamma-tocopherol and beta-carotene by high-performance liquid chromatography
|
Baseline
|
Serum antioxidant power
Ramy czasowe: Baseline
|
Test kit
|
Baseline
|
TNF-alpha in the liver
Ramy czasowe: Baseline
|
Enzyme linked immunosorbent assay
|
Baseline
|
Immunohistochemistry
Ramy czasowe: Baseline
|
Staining for malondialdehyde, alpha-smooth muscle actin, transforming growth factor beta
|
Baseline
|
Free choline in serum
Ramy czasowe: Baseline
|
liquid chromatography/electrospray ionization-isotope dilution mass spectrometry (LC/ESI-IDMS)
|
Baseline
|
Bacterial DNA in plasma
Ramy czasowe: Baseline
|
Quantitative polymerase chain reaction for bacterial 16S rDNA
|
Baseline
|
Insulin resistance
Ramy czasowe: Baseline
|
Fasting glucose and insulin to calculate insulin resistance (HOMA-IR), C-peptide, hemoglobin A1c, all by standard laboratory methods
|
Baseline
|
Plasma ethanol
Ramy czasowe: Baseline
|
standard laboratory measurement
|
Baseline
|
Anthropometry
Ramy czasowe: Baseline
|
Weight, height, skinfolds, bioelectrical impedance analysis
|
Baseline
|
Food intake
Ramy czasowe: Baseline
|
7-day food records
|
Baseline
|
Physical activity
Ramy czasowe: Baseline
|
7 day activity logs
|
Baseline
|
Factors influencing intestinal microbiota
Ramy czasowe: Baseline
|
Environmental questionnaire
|
Baseline
|
Liver function tests
Ramy czasowe: Baseline
|
Alanine transaminase, aspartate transaminase, alkaline phosphatase, standard laboratory tests
|
Baseline
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Johane Allard, MD,FRCPC, University Health Network, Toronto
Publikacje i pomocne linki
Publikacje ogólne
- Schwenger KJ, Allard JP. Clinical approaches to non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Feb 21;20(7):1712-23. doi: 10.3748/wjg.v20.i7.1712.
- Monteiro J, Leslie M, Moghadasian MH, Arendt BM, Allard JP, Ma DW. The role of n - 6 and n - 3 polyunsaturated fatty acids in the manifestation of the metabolic syndrome in cardiovascular disease and non-alcoholic fatty liver disease. Food Funct. 2014 Mar;5(3):426-35. doi: 10.1039/c3fo60551e.
- Mouzaki M, Allard JP. The role of nutrients in the development, progression, and treatment of nonalcoholic fatty liver disease. J Clin Gastroenterol. 2012 Jul;46(6):457-67. doi: 10.1097/MCG.0b013e31824cf51e.
- Mouzaki M, Allard J. Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic. Ann Gastroenterol. 2012;25(3):207-217.
- Da Silva HE, Arendt BM, Noureldin SA, Therapondos G, Guindi M, Allard JP. A cross-sectional study assessing dietary intake and physical activity in Canadian patients with nonalcoholic fatty liver disease vs healthy controls. J Acad Nutr Diet. 2014 Aug;114(8):1181-94. doi: 10.1016/j.jand.2014.01.009. Epub 2014 Mar 14.
- Arendt BM, Ma DW, Simons B, Noureldin SA, Therapondos G, Guindi M, Sherman M, Allard JP. Nonalcoholic fatty liver disease is associated with lower hepatic and erythrocyte ratios of phosphatidylcholine to phosphatidylethanolamine. Appl Physiol Nutr Metab. 2013 Mar;38(3):334-40. doi: 10.1139/apnm-2012-0261. Epub 2012 Oct 15.
- Mouzaki M, Comelli EM, Arendt BM, Bonengel J, Fung SK, Fischer SE, McGilvray ID, Allard JP. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013 Jul;58(1):120-7. doi: 10.1002/hep.26319. Epub 2013 May 14.
- Allard JP, Aghdassi E, Mohammed S, Raman M, Avand G, Arendt BM, Jalali P, Kandasamy T, Prayitno N, Sherman M, Guindi M, Ma DW, Heathcote JE. Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. J Hepatol. 2008 Feb;48(2):300-7. doi: 10.1016/j.jhep.2007.09.009. Epub 2007 Nov 20.
- Arendt BM, Comelli EM, Ma DW, Lou W, Teterina A, Kim T, Fung SK, Wong DK, McGilvray I, Fischer SE, Allard JP. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology. 2015 May;61(5):1565-78. doi: 10.1002/hep.27695. Epub 2015 Feb 27.
- Pettinelli P, Arendt BM, Schwenger KJP, Sivaraj S, Bhat M, Comelli EM, Lou W, Allard JP. Relationship Between Hepatic Gene Expression, Intestinal Microbiota, and Inferred Functional Metagenomic Analysis in NAFLD. Clin Transl Gastroenterol. 2022 Jul 1;13(7):e00466. doi: 10.14309/ctg.0000000000000466. Epub 2022 Feb 10.
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- 03-0505-A
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .